{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,12]],"date-time":"2026-07-12T04:18:34Z","timestamp":1783829914223,"version":"3.55.0"},"reference-count":73,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute (NCI)","doi-asserted-by":"publisher","award":["1K12CA167540"],"award-info":[{"award-number":["1K12CA167540"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health (NIH)","doi-asserted-by":"publisher","award":["UL1 TR000448"],"award-info":[{"award-number":["UL1 TR000448"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Clinical and Translational Science Award (CTSA)"},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences (NCATS)","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","geriatriconcology.net","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Geriatric Oncology"],"published-print":{"date-parts":[[2017,1]]},"DOI":"10.1016\/j.jgo.2016.04.001","type":"journal-article","created":{"date-parts":[[2016,5,12]],"date-time":"2016-05-12T17:46:22Z","timestamp":1463075182000},"page":"1-7","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"title":["Management of multiple myeloma in older adults: Gaining ground with geriatric assessment"],"prefix":"10.1016","volume":"8","author":[{"given":"Tanya M.","family":"Wildes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3820-3260","authenticated-orcid":false,"given":"Erica","family":"Campagnaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.jgo.2016.04.001_bb0005","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1182\/blood-2014-10-609461","article-title":"Future distribution of multiple myeloma in the United States by sex, age, and race\/ethnicity","volume":"125","author":"Rosenberg","year":"2015","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.jgo.2016.04.001_bb0010","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1038\/leu.2013.313","article-title":"Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients","volume":"28","author":"Kumar","year":"2014","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.jgo.2016.04.001_bb0015","doi-asserted-by":"crossref","first-page":"980","DOI":"10.3324\/haematol.2012.075051","article-title":"Age and organ damage correlate with poor survival in myeloma patients: meta-analysis of 1435 individual patient data from 4 randomized trials","volume":"98","author":"Bringhen","year":"2013","journal-title":"Haematologica"},{"issue":"34","key":"10.1016\/j.jgo.2016.04.001_bb0020","doi-asserted-by":"crossref","first-page":"5101","DOI":"10.1200\/JCO.2010.29.8216","article-title":"Bortezomib\u2013melphalan\u2013prednisone\u2013thalidomide followed by maintenance with bortezomib\u2013thalidomide compared with bortezomib\u2013melphalan\u2013prednisone for initial treatment of multiple myeloma: a randomized controlled trial","volume":"28","author":"Palumbo","year":"2010","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.jgo.2016.04.001_bb0025","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1111\/bjh.12465","article-title":"Survival of multiple myeloma patients in the era of novel therapies confirms the improvement in patients younger than 75years: a population-based analysis","volume":"163","author":"Pozzi","year":"2013","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jgo.2016.04.001_bb0030","unstructured":"NCCN Clinical Practice Guidelines in Oncology: Multiple Myeloma. www.nccn.orgprofessionalsphysicianglsPDFmyeloma.pdf."},{"issue":"12","key":"10.1016\/j.jgo.2016.04.001_bb0035","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International myeloma working group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol"},{"issue":"15","key":"10.1016\/j.jgo.2016.04.001_bb0040","doi-asserted-by":"crossref","first-page":"3412","DOI":"10.1200\/JCO.2005.04.242","article-title":"International staging system for multiple myeloma","volume":"23","author":"Greipp","year":"2005","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.jgo.2016.04.001_bb0045","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.clml.2013.07.003","article-title":"Multiple myeloma international staging system: \u201cstaging\u201d or simply \u201caging\u201d system?","volume":"13","author":"Bataille","year":"2013","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"26","key":"10.1016\/j.jgo.2016.04.001_bb0050","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1200\/JCO.2015.61.2267","article-title":"Revised international staging system for multiple myeloma: a report from international myeloma working group","volume":"33","author":"Palumbo","year":"2015","journal-title":"J Clin Oncol"},{"issue":"22","key":"10.1016\/j.jgo.2016.04.001_bb0055","doi-asserted-by":"crossref","first-page":"2806","DOI":"10.1200\/JCO.2012.46.2598","article-title":"Chromosomal abnormalities are major prognostic factors in elderly patients with multiple myeloma: the intergroupe francophone du my\u00e9lome experience","volume":"31","author":"Avet-Loiseau","year":"2013","journal-title":"J Clin Oncol"},{"issue":"13","key":"10.1016\/j.jgo.2016.04.001_bb0060","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1182\/blood-2014-12-615187","article-title":"Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an international myeloma working group report","volume":"125","author":"Palumbo","year":"2015","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.jgo.2016.04.001_bb0065","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.clml.2013.03.013","article-title":"Validation of the Freiburg comorbidity index in 466 multiple myeloma patients and combination with the international staging system are highly predictive for outcome","volume":"13","author":"Kleber","year":"2013","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"6","key":"10.1016\/j.jgo.2016.04.001_bb0070","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.clml.2012.06.008","article-title":"Assessment of vulnerability measures and their effect on survival in a real-life population of multiple myeloma patients registered at Marche Region Multiple Myeloma Registry","volume":"12","author":"Offidani","year":"2012","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"4","key":"10.1016\/j.jgo.2016.04.001_bb0075","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1111\/j.1600-0609.2012.01828.x","article-title":"Pre-existing diabetes mellitus in patients with multiple myeloma","volume":"89","author":"Chou","year":"2012","journal-title":"Eur J Haematol"},{"issue":"3","key":"10.1016\/j.jgo.2016.04.001_bb0080","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1038\/bjc.2014.307","article-title":"The association of diabetes and anti-diabetic medications with clinical outcomes in multiple myeloma","volume":"111","author":"Wu","year":"2014","journal-title":"Br J Cancer"},{"issue":"7","key":"10.1016\/j.jgo.2016.04.001_bb0085","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1007\/s00520-013-1766-y","article-title":"Falls and functional impairments in cancer survivors with chemotherapy-induced peripheral neuropathy (CIPN): a University of Rochester CCOP study","volume":"21","author":"Gewandter","year":"2013","journal-title":"Support Care Cancer"},{"issue":"5","key":"10.1016\/j.jgo.2016.04.001_bb0090","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/S1470-2045(11)70081-X","article-title":"Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study","volume":"12","author":"Moreau","year":"2011","journal-title":"Lancet Oncol"},{"issue":"7","key":"10.1016\/j.jgo.2016.04.001_bb0095","doi-asserted-by":"crossref","first-page":"964","DOI":"10.3324\/haematol.2015.124347","article-title":"Subcutaneous versus intravenous bortezomib in two different induction therapies for newly diagnosed multiple myeloma: an interim analysis from the prospective GMMG-MM5 trial","volume":"100","author":"Merz","year":"2015","journal-title":"Haematologica"},{"issue":"23","key":"10.1016\/j.jgo.2016.04.001_bb0100","doi-asserted-by":"crossref","first-page":"4745","DOI":"10.1182\/blood-2010-07-294983","article-title":"Efficacy and safety of once-weekly bortezomib in multiple myeloma patients","volume":"116","author":"Bringhen","year":"2010","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.jgo.2016.04.001_bb0105","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.ejca.2006.11.004","article-title":"International Society of Geriatric Oncology (SIOG) recommendations for the adjustment of dosing in elderly cancer patients with renal insufficiency","volume":"43","author":"Lichtman","year":"2007","journal-title":"Eur J Cancer"},{"issue":"4","key":"10.1016\/j.jgo.2016.04.001_bb0110","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1111\/ecc.12302","article-title":"Expert consensus panel guidelines on geriatric assessment in oncology","volume":"24","author":"O'Donovan","year":"2015","journal-title":"Eur J Cancer Care"},{"issue":"9","key":"10.1016\/j.jgo.2016.04.001_bb0115","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.6004\/jnccn.2015.0137","article-title":"Geriatric assessment-guided care processes for older adults: a Delphi Consensus of Geriatric Oncology Experts","volume":"13","author":"Mohile","year":"2015","journal-title":"J Natl Compr Canc Netw"},{"issue":"6","key":"10.1016\/j.jgo.2016.04.001_bb0120","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1053\/j.seminoncol.2008.08.006","article-title":"Assessing decisional capacity in the elderly","volume":"35","author":"Rodin","year":"2008","journal-title":"Semin Oncol"},{"key":"10.1016\/j.jgo.2016.04.001_bb0125","doi-asserted-by":"crossref","DOI":"10.1038\/nrclinonc.2014.147","article-title":"Delirium in patients with cancer: assessment, impact, mechanisms and management","author":"Lawlor","year":"2014","journal-title":"Nat Rev Clin Oncol"},{"issue":"11","key":"10.1016\/j.jgo.2016.04.001_bb0130","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1111\/jgs.13702","volume":"63","year":"2015","journal-title":"J Am Geriatr Soc"},{"issue":"3","key":"10.1016\/j.jgo.2016.04.001_bb0135","doi-asserted-by":"crossref","first-page":"213","DOI":"10.2174\/1574884710666150812141525","article-title":"Ability of older people with dementia or cognitive impairment to manage medicine regimens: a narrative review","volume":"10","author":"Elliott","year":"2015","journal-title":"Curr Clin Pharmacol"},{"issue":"1","key":"10.1016\/j.jgo.2016.04.001_bb0140","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1186\/1471-2407-14-496","article-title":"Understanding what matters most to people with multiple myeloma: a qualitative study of views on quality of life","volume":"14","author":"Osborne","year":"2014","journal-title":"BMC Cancer"},{"issue":"1","key":"10.1016\/j.jgo.2016.04.001_bb0145","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1634\/theoncologist.2012-0113","article-title":"Health care costs and resource utilization, including patient burden, associated with novel-agent-based treatment versus other therapies for multiple myeloma: findings using real-world claims data","volume":"18","author":"Teitelbaum","year":"2013","journal-title":"Oncologist"},{"issue":"6","key":"10.1016\/j.jgo.2016.04.001_bb0150","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1007\/s00520-014-2122-6","article-title":"Quantifying the burden of informal caregiving for patients with cancer in Europe","volume":"22","author":"Goren","year":"2014","journal-title":"Support Care Cancer"},{"issue":"17 Suppl.","key":"10.1016\/j.jgo.2016.04.001_bb0155","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1188\/13.CJON.S2.25-32","article-title":"Caregivers of multiple myeloma survivors","author":"Kurtin","year":"2013","journal-title":"Clin J Oncol Nurs"},{"issue":"1","key":"10.1016\/j.jgo.2016.04.001_bb0160","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s00520-009-0793-1","article-title":"Living with multiple myeloma: experiences of patients and their informal caregivers","volume":"19","author":"Molassiotis","year":"2011","journal-title":"Support Care Cancer"},{"issue":"1","key":"10.1016\/j.jgo.2016.04.001_bb0165","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1002\/pon.1710","article-title":"Unmet supportive care needs, psychological well-being and quality of life in patients living with multiple myeloma and their partners","volume":"20","author":"Molassiotis","year":"2011","journal-title":"Psychooncology"},{"issue":"11","key":"10.1016\/j.jgo.2016.04.001_bb0170","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1056\/NEJMra1011442","article-title":"Multiple myeloma","volume":"364","author":"Palumbo","year":"2011","journal-title":"N Engl J Med"},{"issue":"17","key":"10.1016\/j.jgo.2016.04.001_bb0175","doi-asserted-by":"crossref","first-page":"4519","DOI":"10.1182\/blood-2011-06-358812","article-title":"Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European myeloma network (EMN)","volume":"118","author":"Palumbo","year":"2011","journal-title":"Blood"},{"issue":"9513","key":"10.1016\/j.jgo.2016.04.001_bb0180","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/S0140-6736(06)68338-4","article-title":"Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial","volume":"367","author":"Palumbo","year":"2006","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.jgo.2016.04.001_bb0185","doi-asserted-by":"crossref","first-page":"3107","DOI":"10.1182\/blood-2008-04-149427","article-title":"Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial","volume":"112","author":"Palumbo","year":"2008","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.jgo.2016.04.001_bb0190","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1182\/blood-2009-08-237974","article-title":"Melphalan and prednisone plus thalidomide or placebo in elderly patients with multiple myeloma","volume":"116","author":"Waage","year":"2010","journal-title":"Blood"},{"issue":"9594","key":"10.1016\/j.jgo.2016.04.001_bb0195","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1016\/S0140-6736(07)61537-2","article-title":"Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99\u201306): a randomised trial","volume":"370","author":"Facon","year":"2007","journal-title":"Lancet"},{"issue":"22","key":"10.1016\/j.jgo.2016.04.001_bb0200","doi-asserted-by":"crossref","first-page":"3664","DOI":"10.1200\/JCO.2008.21.0948","article-title":"Efficacy of melphalan and prednisone plus thalidomide in patients older than 75years with newly diagnosed multiple myeloma: IFM 01\/01 trial","volume":"27","author":"Hulin","year":"2009","journal-title":"J Clin Oncol"},{"issue":"19","key":"10.1016\/j.jgo.2016.04.001_bb0205","doi-asserted-by":"crossref","first-page":"3160","DOI":"10.1200\/JCO.2009.26.1610","article-title":"Phase III study of the value of thalidomide added to melphalan plus prednisone in elderly patients with newly diagnosed multiple myeloma: the HOVON 49 study","volume":"28","author":"Wijermans","year":"2010","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.jgo.2016.04.001_bb0210","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/j.1600-0609.2010.01524.x","article-title":"Addition of thalidomide to oral melphalan\/prednisone in patients with multiple myeloma not eligible for transplantation: results of a randomized trial from the Turkish Myeloma Study Group","volume":"86","author":"Beksac","year":"2011","journal-title":"Eur J Haematol"},{"issue":"5","key":"10.1016\/j.jgo.2016.04.001_bb0215","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1182\/blood-2011-03-341669","article-title":"Thalidomide for previously untreated elderly patients with multiple myeloma: meta-analysis of 1685 individual patient data from 6 randomized clinical trials","volume":"118","author":"Fayers","year":"2011","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.jgo.2016.04.001_bb0220","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1038\/leu.2010.313","article-title":"Melphalan and prednisone versus melphalan, prednisone and thalidomide for elderly and\/or transplant ineligible patients with multiple myeloma: a meta-analysis","volume":"25","author":"Kapoor","year":"2011","journal-title":"Leukemia"},{"issue":"19","key":"10.1016\/j.jgo.2016.04.001_bb0225","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1056\/NEJMoa1112704","article-title":"Continuous lenalidomide treatment for newly diagnosed multiple myeloma","volume":"366","author":"Palumbo","year":"2012","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.jgo.2016.04.001_bb0230","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.3109\/10428194.2013.847933","article-title":"Factors that influence health-related quality of life in newly diagnosed patients with multiple myeloma aged \u226565years treated with melphalan, prednisone and lenalidomide followed by lenalidomide maintenance: results of a randomized trial","volume":"55","author":"Dimopoulos","year":"2014","journal-title":"Leuk Lymphoma"},{"issue":"10","key":"10.1016\/j.jgo.2016.04.001_bb0235","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1056\/NEJMoa1402551","article-title":"Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma","volume":"371","author":"Benboubker","year":"2014","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.jgo.2016.04.001_bb0240","doi-asserted-by":"crossref","first-page":"826","DOI":"10.3324\/haematol.2014.120121","article-title":"Health-related quality-of-life in patients with newly diagnosed multiple myeloma in the FIRST trial: lenalidomide plus low-dose dexamethasone versus melphalan, prednisone, thalidomide","volume":"100","author":"Delforge","year":"2015","journal-title":"Haematologica"},{"issue":"30","key":"10.1016\/j.jgo.2016.04.001_bb0245","doi-asserted-by":"crossref","first-page":"3459","DOI":"10.1200\/JCO.2014.60.2466","article-title":"Continuous therapy versus fixed duration of therapy in patients with newly diagnosed multiple myeloma","volume":"33","author":"Palumbo","year":"2015","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.jgo.2016.04.001_bb0250","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1056\/NEJMoa0801479","article-title":"Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma","volume":"359","author":"San Miguel","year":"2008","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.jgo.2016.04.001_bb0255","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/j.1600-0609.2012.01788.x","article-title":"Health-related quality of life in elderly, newly diagnosed multiple myeloma patients treated with VMP vs. MP: results from the VISTA trial","volume":"89","author":"Delforge","year":"2012","journal-title":"Eur J Haematol"},{"issue":"33","key":"10.1016\/j.jgo.2016.04.001_bb0260","doi-asserted-by":"crossref","first-page":"3921","DOI":"10.1200\/JCO.2014.58.7618","article-title":"Community-based phase IIIB trial of three UPFRONT bortezomib-based myeloma regimens","volume":"33","author":"Niesvizky","year":"2015","journal-title":"J Clin Oncol"},{"issue":"21","key":"10.1016\/j.jgo.2016.04.001_bb0265","doi-asserted-by":"crossref","first-page":"3454","DOI":"10.1182\/blood.V124.21.3454.3454","article-title":"A phase II study of modified lenalidomide, bortezomib, and dexamethasone (RVD lite) for transplant-ineligible patients with newly diagnosed multiple myeloma","volume":"124","author":"O'Donnell","year":"2014","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.jgo.2016.04.001_bb0270","doi-asserted-by":"crossref","first-page":"128","DOI":"10.6004\/jnccn.2014.0010","article-title":"Hematopoietic stem cell transplantation for hematologic malignancies in older adults: geriatric principles in the transplant clinic","volume":"12","author":"Wildes","year":"2014","journal-title":"J Natl Compr Canc Netw"},{"issue":"8","key":"10.1016\/j.jgo.2016.04.001_bb0275","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1002\/ajh.21191","article-title":"Autologous stem cell transplantation in patients of 70years and older with multiple myeloma: results from a matched pair analysis","volume":"83","author":"Kumar","year":"2008","journal-title":"Am J Hematol"},{"issue":"1","key":"10.1016\/j.jgo.2016.04.001_bb0280","doi-asserted-by":"crossref","first-page":"30","DOI":"10.5144\/1658-3876.2011.30","article-title":"Age at transplantation and outcome after autologous stem cell transplantation in elderly patients with multiple myeloma","volume":"4","author":"Cheikh El","year":"2011","journal-title":"Hematol Oncol Stem Cell Ther"},{"issue":"1","key":"10.1016\/j.jgo.2016.04.001_bb0285","doi-asserted-by":"crossref","first-page":"63","DOI":"10.2169\/internalmedicine.52.8390","article-title":"Evaluation of the feasibility and efficacy of autologous stem cell transplantation in elderly patients with multiple myeloma","volume":"52","author":"Muta","year":"2013","journal-title":"Intern Med"},{"issue":"8","key":"10.1016\/j.jgo.2016.04.001_bb0290","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1056\/NEJM199602223340802","article-title":"Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group","volume":"334","author":"Berenson","year":"1996","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.jgo.2016.04.001_bb0295","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1002\/cncr.11701","article-title":"Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial","volume":"98","author":"Rosen","year":"2003","journal-title":"Cancer"},{"issue":"21","key":"10.1016\/j.jgo.2016.04.001_bb0300","doi-asserted-by":"crossref","first-page":"6030","DOI":"10.1158\/1078-0432.CCR-12-3211","article-title":"Long-term follow-up of MRC myeloma IX trial: survival outcomes with bisphosphonate and thalidomide treatment","volume":"19","author":"Morgan","year":"2013","journal-title":"Clin Cancer Res"},{"issue":"18","key":"10.1016\/j.jgo.2016.04.001_bb0305","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1200\/JCO.2012.47.7901","article-title":"International myeloma working group recommendations for the treatment of multiple myeloma-related bone disease","volume":"31","author":"Terpos","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jgo.2016.04.001_bb0310","first-page":"9501","article-title":"CALGB 70604 (Alliance): a randomized phase III study of standard dosing vs. longer interval dosing of zoledronic acid in metastatic cancer","volume":"33S","author":"Himelstein","year":"2015","journal-title":"J Clin Oncol Annu Meet Abstr"},{"issue":"10","key":"10.1016\/j.jgo.2016.04.001_bb0315","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1016\/S1470-2045(10)70198-4","article-title":"Effect of pamidronate 30mg versus 90mg on physical function in patients with newly diagnosed multiple myeloma (Nordic Myeloma Study Group): a double-blind, randomised controlled trial","volume":"11","author":"Gimsing","year":"2010","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.jgo.2016.04.001_bb0320","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1093\/annonc\/mdn554","article-title":"Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid","volume":"20","author":"Dimopoulos","year":"2009","journal-title":"Ann Oncol"},{"issue":"7","key":"10.1016\/j.jgo.2016.04.001_bb0325","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1093\/jjco\/hyr063","article-title":"Efficacy of continuous, daily, oral, ultra-low-dose 200mg acyclovir to prevent herpes zoster events among bortezomib-treated patients: a report from retrospective study","volume":"41","author":"Aoki","year":"2011","journal-title":"Jpn J Clin Oncol"},{"issue":"3","key":"10.1016\/j.jgo.2016.04.001_bb0330","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1093\/jjco\/hyq194","article-title":"Low-dose acyclovir is effective for prevention of herpes zoster in myeloma patients treated with bortezomib: a report from the Korean Multiple Myeloma Working Party (KMMWP) retrospective study","volume":"41","author":"Kim","year":"2011","journal-title":"Jpn J Clin Oncol"},{"issue":"2","key":"10.1016\/j.jgo.2016.04.001_bb0335","doi-asserted-by":"crossref","first-page":"151","DOI":"10.3816\/CLM.2009.n.036","article-title":"Varicella-zoster virus prophylaxis with low-dose acyclovir in patients with multiple myeloma treated with bortezomib","volume":"9","author":"Pour","year":"2009","journal-title":"Clin Lymphoma Myeloma"},{"issue":"12","key":"10.1016\/j.jgo.2016.04.001_bb0340","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1038\/leu.2012.124","article-title":"Oral antibiotic prophylaxis of early infection in multiple myeloma: a URCC\/ECOG randomized phase III study","volume":"26","author":"Vesole","year":"2012","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.jgo.2016.04.001_bb0345","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1038\/sj.leu.2405062","article-title":"Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma","volume":"22","author":"Palumbo","year":"2008","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.jgo.2016.04.001_bb0350","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1160\/TH13-02-0140","article-title":"MELISSE, a large multicentric observational study to determine risk factors of venous thromboembolism in patients with multiple myeloma treated with immunomodulatory drugs","volume":"110","author":"Leleu","year":"2013","journal-title":"Thromb Haemost"},{"issue":"8","key":"10.1016\/j.jgo.2016.04.001_bb0355","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1200\/JCO.2010.31.6844","article-title":"Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open-label, randomized trial","volume":"29","author":"Palumbo","year":"2011","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.jgo.2016.04.001_bb0360","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1111\/j.1526-4637.2009.00699.x","article-title":"Pharmacological management of persistent pain in older persons","volume":"10","author":"American Geriatrics Society Panel on the Pharmacological Management of Persistent Pain in Older Persons","year":"2009","journal-title":"Pain Med"},{"issue":"1","key":"10.1016\/j.jgo.2016.04.001_bb0365","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/j.1365-2141.2011.08574.x","article-title":"Guidelines for supportive care in multiple myeloma 2011","volume":"154","author":"Snowden","year":"2011","journal-title":"Br J Haematol"}],"container-title":["Journal of Geriatric Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879406816300273?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879406816300273?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,9,19]],"date-time":"2020-09-19T19:22:03Z","timestamp":1600543323000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1879406816300273"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1]]},"references-count":73,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,1]]}},"alternative-id":["S1879406816300273"],"URL":"https:\/\/doi.org\/10.1016\/j.jgo.2016.04.001","relation":{},"ISSN":["1879-4068"],"issn-type":[{"value":"1879-4068","type":"print"}],"subject":[],"published":{"date-parts":[[2017,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Management of multiple myeloma in older adults: Gaining ground with geriatric assessment","name":"articletitle","label":"Article Title"},{"value":"Journal of Geriatric Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jgo.2016.04.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}